Proactiveinvestors Australia

• 

  02/04/2013

  Allied Healthcare lodges U.S. premarket notification for heart tissue patch

• 

  26/02/2013

  Allied Healthcare Group rated ‘outperform’ by RBS Morgans, $0.061 price target

• 

  23/01/2013

  Allied Healthcare Group completes A$4.6M raising to launch CardioCel®

• 

  20/12/2012

  Allied Healthcare Group: Coridon’s Ian Frazer receives grant for HPV vaccine development

• 

  17/12/2012

  Allied Healthcare Group completes oversubscribed A$1.7M capital raising

• 

  15/11/2012

  Allied Healthcare Group highlights success of Coridon’s HPV vaccine

• 

  07/11/2012

  Allied Healthcare Group new contract win, a portent of further growth

• 

  18/10/2012

  Allied Healthcare Group’s cardiovascular tissue patch implanted in first patients

• 

  26/09/2012

  Allied Healthcare Group’s cardiovascular tissue patch authorised by TGA for early use

• 

  04/09/2012

  Allied Healthcare Group receives Buy Recommendation from RBS Morgans

• 

  03/07/2012

  Allied Healthcare Group increases commercial potential of ADAPT® technology with CSIRO partnership

• 

  26/04/2012

  Allied Healthcare Group well supported by market, raises $2m to increase Coridon ownership

• 

  29/03/2012

  Allied Healthcare Group advances towards clinical trials of ADAPT® technology with further success

• 

  13/03/2012

  Allied Healthcare Group successfully implants cardiovascular patch for valve reconstruction

• 

  28/02/2012

  Allied Healthcare Group: Coridon targets $1.5b HPV market, developing next generation vaccine

• 

  05/12/2011

  Allied Healthcare Group technology could extend implanted tissue lifespan, in distribution talks

• 

  01/12/2011

  Allied Healthcare Group: Broker places "Speculative Buy," $0.10 price target

• 

  22/11/2011

  Allied Healthcare Group appoints key executive to biotechnology company, Celxcel

• 

  18/11/2011

  Allied Healthcare Group on the cusp of building a global healthcare company

• 20/05/13

  Allied Healthcare Group shares ride high on back of strong prospects for its CardioCel product

• 29/04/13

  Allied Healthcare Group on track for A$7M in sales for FY2013

• 08/04/13

  Allied Healthcare: More surgeons opt for early access to Cardiocel

• 06/03/13

  Allied Healthcare Group’s CardioCel® trial positive with no calcification after four years

• 13/02/13

  Allied Healthcare Group closer to CE Mark approval for CardioCel®

• 30/01/13

  Allied Healthcare Group looks for further revenue growth in 2013

• 10/01/13

  Allied Healthcare Group unlocks further potential of regenerative tissue technology

• 13/12/12

  Allied Healthcare Group to raise capital

• 28/11/12

  Allied Healthcare Group proves heart patch capable of tissue regeneration

• 05/06/12

  Allied Healthcare Group moves closer to commercialisation of cardiovascular patch

• 21/05/12

  Allied Healthcare Group adds former CSL executive’s expertise to board

• 02/05/12

  Allied Healthcare Group substantial shareholder The Metal Group moves to 17.84% interest

• 27/04/12

  Allied Healthcare Group increases stake in Coridon to 44%

• 17/04/12

  Allied Healthcare Group: Coridon secures licence to vector technology

• 05/04/12

  Allied Healthcare Group further proves up commercial benefits of tissue technology

• 19/03/12

  Allied Healthcare Group granted Singapore patent, boosts commercial prospects for ADAPT®

• 16/03/12

  Allied Healthcare Group to boost kitty by A$6.36m to advance Coridon vaccines

• 14/03/12

  Allied Healthcare Group soon to release capital raising announcement, granted halt

• 05/03/12

  Allied Healthcare Group advances regulatory approval

• 07/12/11

  Allied Healthcare Group: Dr Julian Chick to fill the chief operating officer’s seat

• 11/10/11

  Allied Healthcare Group reports on Coridon testing against Herpes Simplex Virus 2 using DNA vaccine

Sorry, no media files found.